Immuneering annual current ratio
2020
2021
2022
2023
2024
2025
Immuneering Current Ratio Growth & History (IMRX)
Immuneering's current ratio was 17.50 for fiscal 2025.
View full Immuneering company overviewImmuneering annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 17.50 | 12.22 | +231.63% |
| 2024 | 2024-12-31 | 5.28 | −6.08 | −53.54% |
| 2023 | 2023-12-31 | 11.35 | −2.15 | −15.90% |
| 2022 | 2022-12-31 | 13.50 | −13.54 | −50.06% |
| 2021 | 2021-12-31 | 27.04 | 10.31 | +61.66% |
| 2020 | 2020-12-31 | 16.73 | — | — |
Immuneering quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 19.47 | 15.76 | +425.69% |
| Q1 2026 | 2026-03-31 | 32.45 | 24.97 | +333.84% |
| Q4 2025 | 2025-12-31 | 17.50 | 12.22 | +231.63% |
| Q3 2025 | 2025-09-30 | 24.00 | 16.02 | +200.56% |
| Q2 2025 | 2025-06-30 | 3.70 | −5.69 | −60.57% |
| Q1 2025 | 2025-03-31 | 7.48 | −6.90 | −47.98% |
| Q4 2024 | 2024-12-31 | 5.28 | −6.08 | −53.54% |
| Q3 2024 | 2024-09-30 | 7.99 | −9.90 | −55.36% |
| Q2 2024 | 2024-06-30 | 9.39 | −10.96 | −53.85% |
| Q1 2024 | 2024-03-31 | 14.38 | −2.67 | −15.68% |
| Q4 2023 | 2023-12-31 | 11.35 | −2.15 | −15.90% |
| Q3 2023 | 2023-09-30 | 17.89 | 1.35 | +8.15% |
| Q2 2023 | 2023-06-30 | 20.35 | −13.64 | −40.12% |
| Q1 2023 | 2023-03-31 | 17.05 | −20.93 | −55.10% |
| Q4 2022 | 2022-12-31 | 13.50 | −13.54 | −50.06% |
| Q3 2022 | 2022-09-30 | 16.54 | −12.57 | −43.17% |
| Q2 2022 | 2022-06-30 | 33.99 | 23.34 | +219.28% |
| Q1 2022 | 2022-03-31 | 37.98 | — | — |
| Q4 2021 | 2021-12-31 | 27.04 | 10.31 | +61.66% |
| Q3 2021 | 2021-09-30 | 29.11 | — | — |
| Q2 2021 | 2021-06-30 | 10.65 | — | — |
| Q4 2020 | 2020-12-31 | 16.73 | — | — |
Immuneering current ratio trends
Over the last five fiscal years, Immuneering's current ratio increased from 16.73 to 17.50, a change of 0.77. The latest reported quarter, Q2 2026, shows 19.47.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗